Abstract: The invention provides a user verification system to verify whether a user of a secure system is authorised to access the secure system. The user verification system comprises one or more processors and one or more computer memory storage means; stored instructions on the memory storage means for controlling the processor, to create a user profile for a user, which profile input fields require first address such as an email address and second address such as a cellular telephone number; and stored instructions on the memory storage means for controlling the processor, to login to the secure system and which secure system is set up to send a login verification means to the first or second address in the form of a hidden response request.

Abstract: A two-compartment capsule includes a body, a diaphragm between, which seals off the body and provides a first compartment to hold a first dry ingredient, and a cap applied to the body whereby a space between the inner portion of the cap and the diaphragm defines a second compartment for holding a second dry ingredient. This disclosure also provides particular formulations for use in such a capsule. Examples include a probiotic, a digestive enzyme, an expectorant, a bronchodilator, a stool softener, a platelet aggregation inhibitor, a form or derivative of vitamin E, a statin, and aspirin.

Abstract: A comestible gelatin capsule 10 for holding a substance in hermetic isolation includes a capsule body 12, a diaphragm 14 located within the capsule body and an end cap 16. Overlapping open end regions of walls 22 and 28 of the capsule body 12 and of the diaphragm 14, respectively, are fused to one another in a fusion welding process wherein the end regions undergo partial phase change so as to form a circumferential fused homogeneous sealing zone 36. The overlapping end regions are bent inwardly in the fusion welding process such that a portion of the wall 22 extends inwardly across a portion of the wall 28 thereby restricting axial movement of the capsule body and the diaphragm relative to one another forming a stable robust and effective hermetic seal.

Abstract: A two-compartment capsule includes a body, a diaphragm between which seals off the body and provides a first compartment to hold a first ingredient, and a cap applied to the body whereby a space between the inner portion of the cap and the diaphragm defines a second compartment for holding a second ingredient. This disclosure also provides certain ranges for the volumes of the first compartment and the second compartment, as well as a volume ratio of the first compartment to the second compartment, lengths of the first and second compartments, and the length of contact between a sidewall of the diaphragm and a sidewall of the body. Furthermore, particular ingredients and formulations for the two-compartment capsule where volume is critical for a therapeutic effect are disclosed.

Abstract: A multi-compartment capsule may include a body, a diaphragm between, which seals off the body and provides a first compartment to hold an ingredient, and a cap applied to the body whereby a space between the inner portion of the cap and the diaphragm defines a second compartment for holding an oil. A two-compartment capsule may include a body, a diaphragm between, which seals off the body and provides a first compartment to hold an oil, and a cap applied to the body whereby a space between the inner portion of the cap and the diaphragm defines a second compartment for holding an ingredient. The ingredient may have increased bioavailability after exposure to the oil. This disclosure also provides particular formulations for use in such a capsule.

Abstract: A multi-compartment capsule may include a body, a diaphragm between, which seals off the body and provides a first compartment to hold an ingredient, and a cap applied to the body whereby a space between the inner portion of the cap and the diaphragm defines a second compartment for holding an oil. A two-compartment capsule may include a body, a diaphragm between, which seals off the body and provides a first compartment to hold an oil, and a cap applied to the body whereby a space between the inner portion of the cap and the diaphragm defines a second compartment for holding an ingredient. The ingredient may have increased bioavailability after exposure to the oil. This disclosure also provides particular formulations for use in such a capsule.

Abstract: A comestible gelatin capsule 10 for holding a substance in hermetic isolation includes a capsule body 12, a diaphragm 14 located within the capsule body and an end cap 16. Overlapping open end regions of walls 22 and 28 of the capsule body 12 and of the diaphragm 14, respectively, are fused to one another in a fusion welding process wherein the end regions undergo partial phase change so as to form a circumferential fused homogeneous sealing zone 36. The overlapping end regions are bent inwardly in the fusion welding process such that a portion of the wall 22 extends inwardly across a portion of the wall 28 thereby restricting axial movement of the capsule body and the diaphragm relative to one another forming a stable robust and effective hermetic seal.

Abstract: There is provided an antidiabetic enolic glucoside of phenylpyruvic acid and derivatives thereof for use as medicaments, especially normoglycemic agents, i.e. for lowering blood glucose levels to normal levels in mammals that are obese, pre-diabetic or have diabetes, obesity and/or syndrome X. Hence the compounds of the present invention help to manage blood sugar levels, i.e. helping the body by balancing the blood sugar levels; helping to keep balanced blood glucose levels, particularly in humans with diabetes; aiding by enhancing the glucose uptake by the cells and by reducing sugar levels, thus improving or restoring the glucose tolerance; optimizing the glycemic response; normalizing the glucose tolerance.

Abstract: A two-compartment capsule includes a body, a diaphragm between, which seals off the body and provides a first compartment to hold a first dry ingredient, and a cap applied to the body whereby a space between the inner portion of the cap and the diaphragm defines a second compartment for holding a second dry ingredient. This disclosure also provides particular formulations for use in such a capsule. Examples include a probiotic, a digestive enzyme, an expectorant, a bronchodilator, a stool softener, a platelet aggregation inhibitor, a form or derivative of vitamin E, a statin, and aspirin.

Abstract: A two-compartment capsule includes a body, a diaphragm between which seals off the body and provides a first compartment to hold a first ingredient, and a cap applied to the body whereby a space between the inner portion of the cap and the diaphragm defines a second compartment for holding a second ingredient. This disclosure also provides certain ranges for the volumes of the first compartment and the second compartment, as well as a volume ratio of the first compartment to the second compartment, lengths of the first and second compartments, and the length of contact between a sidewall of the diaphragm and a sidewall of the body. Furthermore, particular ingredients and formulations for the two-compartment capsule where volume is critical for a therapeutic effect are disclosed.

Abstract: There is provided an antidiabetic enolic glucoside of phenylpyruvic acid and derivatives thereof for use as medicaments, especially normoglycemic agents, i.e. for lowering blood glucose levels to normal levels in mammals that are obese, pre-diabetic or have diabetes, obesity and/or syndrome X. Hence the compounds of the present invention help to manage blood sugar levels, i.e. helping the body by balancing the blood sugar levels; helping to keep balanced blood glucose levels, particularly in humans with diabetes; aiding by enhancing the glucose uptake by the cells and by reducing sugar levels, thus improving or restoring the glucose tolerance; optimizing the glycemic response; normalizing the glucose tolerance.

Abstract: There is provided an antidiabetic enolic glucoside of phenylpyruvic acid and derivatives thereof for use as medicaments, especially normoglycemic agents, i.e. for lowering blood glucose levels to normal levels in mammals that are obese, pre-diabetic or have diabetes, obesity and/or syndrome X. Hence the compounds of the present invention help to manage blood sugar levels, i.e. helping the body by balancing the blood sugar levels; helping to keep balanced blood glucose levels, particularly in humans with diabetes; aiding by enhancing the glucose uptake by the cells and by reducing sugar levels, thus improving or restoring the glucose tolerance; optimizing the glycemic response; normalizing the glucose tolerance.

Abstract: Novel and useful compositions derived from rooibos for treating diabetes are provided. The present invention is particularly concerned with the treatment of Type 2 diabetes. The invention provides a new use for aspalathin and rutin and compositions containing them for use in the prevention and treatment of diabetes. The invention provides an anti-diabetic agent, an anti-diabetic composition containing the anti-diabetic agent, a foodstuff or beverage containing the anti-diabetic agent, a method for preventing or treating diabetes or impaired glucose tolerance, and a method of decreasing blood glucose level. The anti-diabetic agent may be an extract from rooibos (Aspalathus spp.), aspalathin as such or in combination with rutin.

Abstract: There is provided an antidiabetic enolic glucoside of phenylpyruvic acid and derivatives thereof for use as medicaments, especially normoglycemic agents, i.e. for lowering blood glucose levels to normal levels in mammals that are obese, pre-diabetic or have diabetes, obesity and/or syndrome X. Hence the compounds of the present invention help to manage blood sugar levels, i.e. helping the body by balancing the blood sugar levels; helping to keep balanced blood glucose levels, particularly in humans with diabetes; aiding by enhancing the glucose uptake by the cells and by reducing sugar levels, thus improving or restoring the glucose tolerance; optimizing the glycemic response; normalizing the glucose tolerance.

Abstract: Novel and useful compositions derived from honeybush plant extract for treating diabetes are provided. It has been found that the plant extract of the present invention exhibit a superior antidiabetic effect when administered in an amount from about 1 milligram to about 5 milligrams, preferably to about 2.5 milligrams, per kilogram body weight.

Abstract: Novel and useful compositions derived from rooibos for treating diabetes are provided. The present invention is particularly concerned with the treatment of Type 2 diabetes. The invention provides a new use for aspalathin and rutin and compositions containing them for use in the prevention and treatment of diabetes. The invention provides an antidiabetic agent, an anti-diabetic composition containing the anti-diabetic agent, a foodstuff or beverage containing the anti-diabetic agent, a method for preventing or treating diabetes or impaired glucose tolerance, and a method of decreasing blood glucose level. The anti-diabetic agent may be an extract from rooibos (Aspalathus spp.), aspalathin as such or in combination with rutin.

Abstract: Novel and useful compositions derived from honeybush plant extract for treating diabetes are provided. It has been found that the plant extract of the present invention exhibit a superior antidiabetic effect when administered in an amount from about 1 milligram to about 5 milligrams, preferably to about 2.5 milligrams, per kilogram body weight.